Extended Data Fig. 2: Roles of ARID2 and Ikaros/Aiolos in the growth and gene expression of multiple myeloma cell lines.
From: ARID2 is a pomalidomide-dependent CRL4CRBN substrate in multiple myeloma cells
a, Proliferation (left) and immunoblot (right) analyses of MM.1S cells expressing shRNA against Ikaros. Cells were subjected to immunoblotting 3 days post infection of shRNA expression vectors. Data represent mean ± s.d. (n=3, biologically independent replicates). b,c, Proliferation (left) and immunoblot (right) analyses of OPM2 (b) and H929 (c) cells expressing shRNA against ARID2. Cells were subjected to immunoblotting 3 days (b) or 2 days (c) post infection of shRNA expression vectors. Data represent mean ± s.d. (n=3, biologically independent replicates). d, Analysis of the effect of Aiolos knockdown on ARID2 mRNA (left, 72 h) and protein (right) levels in MM.1S. The Aiolos and beta-actin blots shown here are identical to those shown in Fig. 2b. e, Heat map showing log10-scaled p-values. Fisher’s exact test (two-sided) was used to compare genes up- or down-regulated by pomalidomide treatment, ARID2 knockdown, or Aiolos knockdown (related to Fig. 2c). f, 1,300 pomalidomide-affected genes were grouped into seven clusters based on their expression values are shown as a heat map (related to Fig. 2d). Data in a–d were independently repeated twice with similar results.
